<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="191747"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Hepatitis B virus replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug coating</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-01-19T00:00:00Z</DateChangeLast><Identifiers><Identifier>MACS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tenofovir disoproxil fumarate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1233</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this observational, cohort, MACS (Multicenter AIDS Cohort Study) study was to evaluate the association between elevated levels of monocyte activation markers (soluble CD163 and CD14) and subclinical atherosclerosis in patients with or without HIV infection [ 1563492 ]. The prevalence rate (PR) of positive coronary arterial remodeling was also evaluated using coronary computed tomography angiography in these patients [ 1729202 ]. The association between cumulative tenofovir disoproxil</Teaser><TrialCategories><Category>Biomarker identification</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term><Term>Cohort</Term></TermsDesign><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>MACS: An observational, cohort study to evaluate the association between elevated levels of monocyte activation markers and subclinical atherosclerosis and the prevalence of positive coronary arterial remodeling in patients with or without HIV infection</TitleDisplay><BiomarkerNames><BiomarkerName>Alpha-1-microglobulin </BiomarkerName><BiomarkerName> Hepatitis A virus cellular receptor 1 </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Interleukin-18 </BiomarkerName><BiomarkerName> Monocyte differentiation antigen CD14 </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Procollagen type III-N-terminal peptide </BiomarkerName><BiomarkerName> Scavenger receptor cysteine-rich type 1 protein M130 </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> Total cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>